What is Sales and Marketing Strategy of Zoetis Company?

Dedicated field teams operate in ~45+ countries targeting veterinarians and livestock producers, with focused key account managers for large corporate groups and national customers.

Zoetis leverages major wholesalers for scale and logistics—examples in North America include national players providing practice credit and broad reach into clinics and producers.

Point-of-care analyzers and reference lab services create embedded, recurring revenue and drive pull-through of consumables and diagnostics-driven prescriptions.

Clinic webstores, eRx, and practice management integrations enable ordering, auto-ship programs, and defend prescription capture versus online pharmacies.

Science-backed solutions promise better clinical outcomes and improved practice economics — e.g., itch relief in 24 hours with Apoquel/Cytopoint and monthly protection with Simparica Trio.

Clean, clinical visuals with orange accents convey warmth and scientific rigor; tone is authoritative yet accessible across HCP and consumer channels.

Leverages innovation velocity (biologics/mAbs like Librela and Solensia), product breadth across species and data-enabled services to justify premium positioning.

Maintains ~7–8% of revenue in R&D and offers over 300+ product lines spanning livestock and companion animals.

Objective: cement leadership in canine itch relief using evidence-led stories of rapid relief and quality-of-life gains via vet detailing, CE webinars, KOL roadshows and targeted social to owners; result: dermatology franchise reached a $multi-billion annualized run-rate by the early 2020s with high repeat rates driven by tight HCP education and owner-friendly symptom language.

Objective: capture combo-parasiticide share with a '3-in-1 protection simplified' message plus seasonal adherence nudges across search/social, clinic webstores/autoship, retail media and POS; result: category saw double-digit CAGR with Trio leading U.S. growth and online-enabled adherence in mature clinics reaching 60–70%, showing bundling plus subscription mechanics increased LTV and reduced leakage to online-only pharmacies.

Objective: create and dominate the anti-NGF mAb pain category after U.S. approval by reframing osteoarthritis as a treatable chronic condition with monthly clinic injections; channels included KOL symposia, owner video testimonials and practice finance calculators; result: triple-digit category growth in 2024 and notable clinic traffic from monthly administration.

Objective: unlock underdiagnosed feline OA via owner education on subtle signs using social microvideos, vet CE and in-clinic screening checklists; result: significant penetration in the feline segment, increased visit frequency and diagnostics tie-ins driven by symptom education.

Objective: increase consumables and services utilization by bundling analyzer placements with loyalty pricing and data dashboards; channels: direct sales to clinics/corporate groups and co-marketing at conferences; result: higher per-clinic revenue and stickier relationships—diagnostics utilization correlated with higher Rx capture across categories.

Objective: maintain trust during supply tightness and AMR debates using transparent updates, prioritization guides and stewardship education via HCP portals, email and webinars; result: brand resilience and stable share vs peers during disruptions, underscoring proactive, data-led communication preserves credibility.